Data from EMC - Curated by EPG Health - Last updated 19 August 2016
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Nebcin is indicated for the treatment of the following infections caused by susceptible micro-organisms:
Central nervous system infections, including meningitis, septicaemia and neonatal sepsis
Gastro-intestinal infections, including peritonitis, and other significant infections such as complicated and recurrent urinary tract infections, including pyelonephritis and cystitis
Lower respiratory tract infections, including pneumonia, bronchopneumonia and acute bronchitis
Skin, bone and soft tissue infections, including burns
Nebcin may be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contra-indicated and when bacterial susceptibility testing and clinical judgement indicate its use.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome (LEADERSHIP 301)
This study evaluates the effects of two doses of oral AQX-1125 on bladder pain and other urinary symptoms in subjects with interstitial cystitis/bladder pain syndrome.
Added 8 months ago
Assessment of the Reducting Effect of Dexmedetomidine on the Morphine Use for Severe Burned Patients
The new progresses relative to sedation-analgesia for resuscitation unit lead to perform a light and cooperative sedation as soon as possible in order to decrease the period of mechanical...
Added 2 years ago
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A) versus colistimethate sodium + imipenem+cilastatin in the treatment of...
Added 4 years ago
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
This study will evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks...
Added 1 year ago
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
This study will evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks...
Added 1 year ago
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
The rise in resistant Gram-negative bacteria is a major concern and has led to difficulty in treating multidrug-resistant (MDR) infections....
Added 3 years ago
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
There has been greater interest in developing additional antimicrobial agents due to the increasing health care costs and resistance resulting from bacterial pathogens to currently available treatment options.
Added 1 year ago
Repeated Emergency Department Visits Among Children Admitted With Meningitis or Septicemia: A Population-Based Study
Study objective: Early diagnosis of children with meningitis or septicemia remains a significant challenge in emergency medicine. We seek to...
Added 4 years ago
Hospital admission rates for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in children in England over five decades: a population-based observational study
Background:Infection with Haemophilus influenzae, Neisseria meningitidis, and StreptococcuS pneumoniae causes substantial mortality and long–term morbidity in children. We know of...
Added 5 years ago
This guideline makes recommendations on best practice in the recognition and management of meningococcal disease in children and young people up to 16 years of age.
Added 10 years ago
It provides evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI.
Added 7 years ago
Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal septicaemia (blood poisoning) in babies, children and young people under 16.
Added 8 years ago
|Marketing authorisation holder||Flynn Pharma Ltd|